diff --git a/healthcare/in_the_us.md b/healthcare/in_the_us.md new file mode 100644 index 0000000..96aa7bb --- /dev/null +++ b/healthcare/in_the_us.md @@ -0,0 +1,22 @@ +## Healthcare in the U.S. + +#### U.S. lags behind developed countries on a number of metrics in regards to healthcare, especially in terms of cost-efficiency and effectiveness + +* [OECD 18](https://data.oecd.org/healthres/health-spending.htm) + * **U.S. spends a lot more government money on healthcare per capita than developed countries** that have more successful healthcare systems + * _Note: an [version](https://cdn.discordapp.com/attachments/418850379518705675/640905968686727169/unknown.png) of the data said that voluntary healthcare spending in the U.S. was disproportionately high, but that version is outdated_ +* [Sawyer, Cox 18](https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/#item-since-1980-the-gap-has-widened-between-u-s-health-spending-and-that-of-other-countries___2018) + * U.S. has spent more than other developed countries when it comes to healthcare, and **that gap has widened over time** + + + + +* [U.S. Census Bureau 18](https://www.census.gov/library/publications/2019/demo/p60-267.html) + * *"In 2018, **8.5 percent of people**, or **27.5 million**, did not have health insurance at any point during the year."* + * *"The uninsured rate and number of uninsured increased from 2017 (7.9 percent or 25.6 million)."* +* [Commonwealth Fund: Collins et al. 19](https://www.commonwealthfund.org/publications/issue-briefs/2019/feb/health-insurance-coverage-eight-years-after-aca) + * **45%** of U.S. adults ages 19 to 64 are inadequately insured + * This is nearly the same as in 2010, indicating nearly no imovement + * The survey also includes a methodology that explains the qualifications for being underinsured +* [Gagnon 08](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050001) + * Finds that in the USA, **pharmaceutical companies spend almost twice as much on promotion as they do on R&D**. These numbers clearly show how promotion predominates over R&D in the pharmaceutical industry, contrary to the industry's claim.